TABLE OF CONTENTS

1. Introduction

1.1 The Insight Partners Research Report Guidance

1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

2.2 Market Attractiveness

3. Research Methodology

3.1 Coverage

3.2 Secondary Research

3.3 Primary Research

4. North America Pipeline Studies for Epilepsy Therapy Approaches

4.1 Pipeline Studies for Epilepsy Therapy Approaches

4.1.1 Cell and Gene Therapy Approaches

4.1.2 Encapsulated cell bio delivery (ECB) system

4.1.3 Gene Therapy for Epilepsy Clinical Overview

4.1.3.1 Genetic Therapies Adopted for Clinic Research of Epilepsy

4.1.3.1.1 Gene Supplementation - Overview

4.1.3.1.2 Gene Modulation - Overview

4.1.3.1.3 Antisense Oligonucleotides and RNA Interference - Overview

4.1.3.1.4 Neuropeptides - Overview

4.1.3.1.5 Engineered Channels - Overview

4.1.3.1.6 Endogenous Channels - Overview

4.1.3.2 Pipeline Studies of Viral Vectors for Epilepsy

4.1.3.3 Pipeline Studies of Non-Viral Vectors for Epilepsy

4.1.3.3.1 Polymer-based Non-Viral Vectors for Epilepsy

4.1.3.3.2 Lipid-based Non-Viral Vectors for Epilepsy

4.1.3.4 Adeno-Associated Virus (AAV)-Mediated Neuromodulatory Peptides - Overview

4.1.3.5 Neurotrophic Factors for Gene Therapy Approaches

4.1.3.6 Potassium Channels for Human Epileptic Phenotypes

4.1.3.7 Enzyme Inducing Antiepileptic Drugs

5. North America Epilepsy Market - Key Market Dynamics

5.1 Market Drivers

5.1.1 Rising Prevalence of Epilepsy

5.1.2 Increasing Investments in Development of Epilepsy Therapies

5.2 Market Restraints

5.2.1 Recall of Products

5.3 Market Opportunities

5.3.1 Surge in Awareness Programs Conducted by Organizations

5.4 Future Trends

5.4.1 Gene Therapy as Promising Treatment Approach

5.5 Impact of Drivers and Restraints:

6. Epilepsy Market - North America Analysis

6.1 North America: Epilepsy Market Overview

7. North America Epilepsy Market Analysis - by Type

7.1 Overview

7.2 Progressive Myoclonic Epilepsy

7.2.1 Overview

7.2.2 Progressive Myoclonic Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

7.3 Reflex Epilepsy

7.3.1 Overview

7.3.2 Reflex Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

7.4 Generalized Epilepsy

7.4.1 Overview

7.4.2 Generalized Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

7.5 Other

7.5.1 Overview

7.5.2 Other: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

8. North America Epilepsy Market Analysis - by Route of Administration

8.1 Overview

8.2 Oral

8.2.1 Overview

8.2.2 Oral: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

8.3 Parenteral

8.3.1 Overview

8.3.2 Parenteral: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

8.4 Others

8.4.1 Overview

8.4.2 Others: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

9. North America Epilepsy Market Analysis - by Treatment Type

9.1 Overview

9.2 First Generation Drugs

9.2.1 Overview

9.2.2 First Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

9.3 Second Generation Drugs

9.3.1 Overview

9.3.2 Second Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

9.4 Third Generation Drugs

9.4.1 Overview

9.4.2 Third Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

10. North America Epilepsy Market Analysis - by Age Group

10.1 Overview

10.2 Adult

10.2.1 Overview

10.2.2 Adult: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

10.3 Children

10.3.1 Overview

10.3.2 Children: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

11. North America Epilepsy Market Analysis - by Distribution Channel

11.1 Overview

11.2 Hospital Pharmacies

11.2.1 Overview

11.2.2 Hospital Pharmacies: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

11.3 Retail Pharmacies

11.3.1 Overview

11.3.2 Retail Pharmacies: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

11.4 Others

11.4.1 Overview

11.4.2 Others: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

12. North America Epilepsy Market - Country Analysis

12.1 North America Epilepsy Market Overview

12.1.1 North America: Epilepsy Market Breakdown- by Country, 2022 and 2030 (%)

12.1.1.1.1 United States: Epilepsy Market Overview

12.1.1.1.2 United States: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

12.1.1.1.3 United States: Epilepsy Market Breakdown, by Type

12.1.1.1.4 United States: Epilepsy Market Breakdown, by Route of Administration

12.1.1.1.5 United States: Epilepsy Market Breakdown, by Treatment Type

12.1.1.1.6 United States: Epilepsy Market Breakdown, by Age Group

12.1.1.1.7 United States: Epilepsy Market Breakdown, by Distribution Channel

12.1.1.1.8 Canada: Epilepsy Market Overview

12.1.1.1.9 Canada: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

12.1.1.1.10 Canada: Epilepsy Market Breakdown, by Type

12.1.1.1.11 Canada: Epilepsy Market Breakdown, by Route of Administration

12.1.1.1.12 Canada: Epilepsy Market Breakdown, by Treatment Type

12.1.1.1.13 Canada: Epilepsy Market Breakdown, by Age Group

12.1.1.1.14 Canada: Epilepsy Market Breakdown, by Distribution Channel

12.1.1.1.15 Mexico: Epilepsy Market Overview

12.1.1.2 Mexico: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

12.1.1.2.1 Mexico: Epilepsy Market Breakdown, by Type

12.1.1.2.2 Mexico: Epilepsy Market Breakdown, by Route of Administration

12.1.1.2.3 Mexico: Epilepsy Market Breakdown, by Treatment Type

12.1.1.2.4 Mexico: Epilepsy Market Breakdown, by Age Group

12.1.1.2.5 Mexico: Epilepsy Market Breakdown, by Distribution Channel

13. Industry Landscape

13.1 Overview

13.2 Growth Strategies in Epilepsy Market

13.3 Organic Growth Strategies

13.3.1 Overview

13.4 Inorganic Growth Strategies

13.4.1 Overview

14. Company Profiles

14.1 Abbott Laboratories

14.1.1 Key Facts

14.1.2 Business Description

14.1.3 Products and Services

14.1.4 Financial Overview

14.1.5 SWOT Analysis

14.1.6 Key Developments

14.2 Pfizer Inc

14.2.1 Key Facts

14.2.2 Business Description

14.2.3 Products and Services

14.2.4 Financial Overview

14.2.5 SWOT Analysis

14.2.6 Key Developments

14.3 Eisai Co Ltd

14.3.1 Key Facts

14.3.2 Business Description

14.3.3 Products and Services

14.3.4 Financial Overview

14.3.5 SWOT Analysis

14.3.6 Key Developments

14.4 UCB SA

14.4.1 Key Facts

14.4.2 Business Description

14.4.3 Products and Services

14.4.4 Financial Overview

14.4.5 SWOT Analysis

14.4.6 Key Developments

14.5 LivaNova Plc

14.5.1 Key Facts

14.5.2 Business Description

14.5.3 Products and Services

14.5.4 Financial Overview

14.5.5 SWOT Analysis

14.5.6 Key Developments

14.6 Novartis AG

14.6.1 Key Facts

14.6.2 Business Description

14.6.3 Products and Services

14.6.4 Financial Overview

14.6.5 SWOT Analysis

14.6.6 Key Developments

14.7 Medtronic Plc

14.7.1 Key Facts

14.7.2 Business Description

14.7.3 Products and Services

14.7.4 Financial Overview

14.7.5 SWOT Analysis

14.7.6 Key Developments

14.8 GSK Plc

14.8.1 Key Facts

14.8.2 Business Description

14.8.3 Products and Services

14.8.4 Financial Overview

14.8.5 SWOT Analysis

14.8.6 Key Developments

14.9 H. Lundbeck AS

14.9.1 Key Facts

14.9.2 Business Description

14.9.3 Products and Services

14.9.4 Financial Overview

14.9.5 SWOT Analysis

14.9.6 Key Developments

15. Appendix

15.1 About The Insight Partners

List of Tables

Table 1. North America Epilepsy Market Segmentation

Table 2. Cell Therapy Approach - An Overview

Table 3. Gene Therapy Approach - An Overview

Table 4. Encapsulated cell bio delivery (ECB) system Cell and Gene Therapy Approach - An Overview

Table 5. Preclinically Tested Genetic Therapies for Epilepsy

Table 6. Clinical Trials for Epilepsy Gene Therapy: Overview

Table 7. Viral Vectors Comparison with respect to Various Parameters

Table 8. Subfamilies of Human K+ Channels Involved in Epilepsies

Table 9. Enzyme-Inducing Antiepileptic Drugs

Table 10. Enzyme-Inducing Antiepileptic Drugs & Drug Target Types Overview

Table 11. United States: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million) - by Type

Table 12. United States: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million) - by Route of Administration

Table 13. United States: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million) - by Treatment Type

Table 14. United States: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million) - by Age Group

Table 15. United States: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million) - by Distribution Channel

Table 16. Canada: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million) - by Type

Table 17. Canada: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million) - by Route of Administration

Table 18. Canada: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million) - by Treatment Type

Table 19. Canada: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million) - by Age Group

Table 20. Canada: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million) - by Distribution Channel

Table 21. Mexico: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million) - by Type

Table 22. Mexico: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million) - by Route of Administration

Table 23. Mexico: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million) - by Treatment Type

Table 24. Mexico: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million) - by Age Group

Table 25. Mexico: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million) - by Distribution Channel

Table 26. Recent Organic Growth Strategies in Epilepsy Market

Table 27. Recent Inorganic Growth Strategies in the Epilepsy Market

List of Figures

Figure 1. North America Epilepsy Market Segmentation, by Country

Figure 2. Epilepsy Market - Key Market Dynamics

Figure 3. Impact Analysis of Drivers and Restraints

Figure 4. Epilepsy Market Revenue (US$ Million), 2020-2030

Figure 5. Epilepsy Market Share (%) - by Type (2022 and 2030)

Figure 6. Progressive Myoclonic Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

Figure 7. Reflex Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

Figure 8. Generalized Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

Figure 9. Other: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

Figure 10. Epilepsy Market Share (%) - by Route of Administration (2022 and 2030)

Figure 11. Oral: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

Figure 12. Parenteral: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

Figure 13. Others: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

Figure 14. Epilepsy Market Share (%) - by Treatment Type (2022 and 2030)

Figure 15. First Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

Figure 16. Second Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

Figure 17. Third Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

Figure 18. Epilepsy Market Share (%) - by Age Group (2022 and 2030)

Figure 19. Adult: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

Figure 20. Children: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

Figure 21. Epilepsy Market Share (%) - by Distribution Channel (2022 and 2030)

Figure 22. Hospital Pharmacies: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

Figure 23. Retail Pharmacies: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

Figure 24. Others: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

Figure 25. North America: Epilepsy Market, by Key Country - Revenue (2022) (US$ Million)

Figure 26. North America: Epilepsy Market Breakdown, by Key Countries, 2022 and 2030 (%)

Figure 27. United States: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

Figure 28. Canada: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

Figure 29. Mexico: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

Figure 30. Growth Strategies in Epilepsy Market